Mst Continus (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Mst Continus, is an opioid analgesic presented as an oral tablet for oral use. It provides potent relief of moderate to severe acute and chronic pain, and is indicated for adult patients who require strong analgesia when other treatments are insufficient.

GNH USA supplies Mst Continus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution for this prescription opioid and ensuring timely delivery.

Morphine Sulfate acts on the central nervous system to alleviate severe pain.

Acute pain: provides rapid analgesia for severe short‑term pain episodes Chronic pain: maintains long‑term pain control for persistent severe pain Cancer‑related pain: helps manage moderate to severe pain associated with malignancy Post‑operative pain: reduces pain intensity after surgical procedures

Morphine Sulfate may cause a range of adverse reactions, varying from common to serious.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Addiction or dependence

When prescribing or dispensing Morphine Sulfate, consider the following precautions. - Assess pain severity before initiating therapy: ensure opioid use is appropriate for the level of pain. - Monitor respiratory function especially after dose changes: watch for signs of slowed breathing. - Evaluate for signs of dependence or abuse: conduct regular assessments. - Adjust dose in renal or hepatic impairment: reduced clearance may increase risk of toxicity. - Avoid concomitant use with other CNS depressants: increased sedation and respiratory risk. - Store at ambient temperature: keep in the original packaging, protect from moisture.

Morphine Sulfate interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other opioids: risk of additive respiratory depression. - Benzodiazepines or barbiturates: increased sedation and respiratory depression. - MAO inhibitors: risk of severe hypotension and serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase morphine plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect. - NSAIDs: increased risk of gastrointestinal bleeding.